Tenderwize
Zurück zur Suche

Pharmaceutical products

DAPSA·chanteau, France·Deadline Mar 21, 2030 · 1303 days left·Restricted·Supplies
Registrieren zum Speichern
Originaltitel der Bekanntmachung

France-Fleury-les-Aubrais: Pharmaceutical products

35/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

35 / 100

Komplexität

40 / 100

Risikofaktoren

Critical details such as estimated value, eligibility criteria, and required documents are missing. The notice provides...

Structured data indicates a restricted procedure, while XML notice describes a dynamic purchasing system (DPS). This ma...

Restricted procedure — pre-qualification required

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 3 lots
  • Supply of pharmaceutical products (vaccines, medicines, and parapharmacy products) for operational use by the French Ministry of Defence.
  • The contract covers three distinct lots: vaccines, medicines, and parapharmacy products.
Vollständige Zusammenfassung anzeigen

This is a restricted procedure notice for the supply of pharmaceutical products (vaccines, medicines, and parapharmacy products) for operational purposes, issued by the French Ministry of Defence (ema/dcssa/daps-ssa). The notice was published on 2022-02-14, but the submission deadline is unusually far in the future (2030-03-21), likely indicating a dynamic purchasing system (DPS) despite structured data flags. Three lots are identified from the XML notice. No estimated value is provided. No procurement documents were analyzed beyond the notice itself.

Risiken

Critical details such as estimated value, eligibility criteria, and required documents are missing. The notice provides...

Structured data indicates a restricted procedure, while XML notice describes a dynamic purchasing system (DPS). This ma...

Restricted procedure — pre-qualification required

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Procedure is restricted (structured data) but XML indicates a dynamic purchasing system (inconsistency noted).

Administrative

  • Submission is allowed for all lots (based on XML notice: 'TY TYPE BID: Submission for all lots').
  • Language: French (FRA) is required for submission.

Auftraggeber

Name

DAPSA

Ort

chanteau, FRA

Auftraggeberprofil

Profil öffnen

Kennung

15100002301258

Tätigkeit

Defence

Lose (3)

1

vaccins à visée opérationnelle

Supply of vaccines for operational purposes.

Kategorie

Pharmaceutical products

Frist

Deadline Mar 21, 2030

2

médicaments à visée opérationnelle

Supply of medicines for operational purposes.

Kategorie

Pharmaceutical products

Frist

Deadline Mar 21, 2030

3

produits de parapharmacie à visée opérationnelle

Supply of parapharmacy products for operational purposes.

Kategorie

Pharmaceutical products

Frist

Deadline Mar 21, 2030

Vergabedetails

Veröffentlichungsdatum
14 Feb 2022
Sprachen
French

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
81444-2022

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3